share_log

莱美药业:国金证券关于莱美药业2023年度内部控制评价报告的核查意见

Laimei Pharmaceuticals: Guojin Securities's inspection opinions on Laimei Pharmaceuticals' 2023 internal control evaluation report

深证信a股 ·  Mar 22
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more